Merck & Co Sales Doubles In Q1
Merck & Co has posted a net income of $330.2m for the first quarter of 2010, or $0.09 per diluted share, compared to $1.45bn, or $0.67 per diluted
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.